Financials
Quarterly financials
| (USD) | Mar 2023 | Q/Q |
|---|---|---|
| Revenue | 602K | -57% |
| Gross Profit | 99.7K | -89% |
| Cost Of Revenue | 502.2K | -3% |
| Operating Income | -10MM | -62% |
| Operating Expenses | 10.1MM | -63% |
| Net Income | -5.8MM | -74% |
| R&D | 5MM | +6% |
| G&A | 3MM | -43% |
| Marketing | 1.7MM | +28% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
The latest analyst coverage could presage a bad day for Co-Diagnostics, Inc. ( NASDAQ:CODX ), with the covering analyst...
Co-Diagnostics, Inc. (CODX) delivered earnings and revenue surprises of 13.04% and 45.27%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the quarter ended March 31, 2023.
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is hosting a booth at Argentum's 2023 Senior Living Executive Conference and Expo, being held May 8-10 in New Orleans, LA.
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2023 results on Thursday, May 11, 2023, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts and institutional investors. Management on the call will include Dwight Egan, Chief Executive Off
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the Caribbean Public Health Agency (CARPHA) 67th Annual Health Research Conference, being held in-person April 27-29, 2023, in the Bahamas.
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) April 15-18, 2023, in Copenhagen, Denmark.
As every investor would know, not every swing hits the sweet spot. But really bad investments should be rare. So take a...
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company CEO will deliver the keynote address at the 4th Annual MarketsandMarkets Infectious Disease Diagnostics and Molecular Diagnostics Conference, held March 23-24, 2023, in London, England, where the Company will also be hosting a booth.
Co-Diagnostics, Inc. (NASDAQ:CODX) Q4 2022 Earnings Call Transcript March 16, 2023 Operator: Good afternoon, and welcome to the Co-Diagnostics, Inc. Fourth Quarter and Full Year 2022 Earnings Results Conference Call. All participants will be in a listen-only mode. After today’s presentation, there will be an opportunity to ask questions. Please note that this event is […]